The Fourth Hospital of Harbin Medical University
Welcome,         Profile    Billing    Logout  
 32 Trials 
92 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Wei
NCT02654561: Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation

Recruiting
3
600
RoW
Heparin Sodium, Unfractionated heparin, Saline, Normal saline
China Medical University, China, West China Hospital, Zhongda Hospital, The First Affiliated Hospital of Dalian Medical University, Shengjing Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, The Second Affiliated Hospital of Kunming Medical University, The First Hospital of Qinhuangdao, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Harbin Medical University, Peking University People's Hospital, The People's Hospital of Liaoning Province, Fourth People's Hospital of Shenyang, Beijing Tsinghua Changgeng Hospital, First Affiliated Hospital of Kunming Medical University, The Affiliated Hospital of Qingdao University, Beijing Friendship Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Nanchang University
Sepsis, Disseminated Intravascular Coagulation
12/24
06/25
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
3
85
RoW
Pomalidomide, Dexamethasone
Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma, Recurrent or Refractory
06/22
12/23
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Recruiting
3
192
RoW
Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment
Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
12/24
12/26
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Recruiting
3
51
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
10/25
12/25
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Recruiting
3
111
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor
10/26
12/26
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
3
648
RoW
AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
12/26
12/26
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia

Recruiting
3
170
RoW
IMM01, Timdarpacept, Azacitidine, Placebo
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Chronic Myelomonocytic Leukemia
10/26
10/29
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/25
05/26
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting
3
218
RoW
ICP-022, Chlorambucil, Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
06/25
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting
3
356
RoW
Orelabrutinib and R-CHOP, R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
12/24
12/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT05618470: Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Recruiting
2/3
80
RoW
Wumeiwan Jiawei Fang, nothing, botulinum toxin A
China Academy of Chinese Medical Sciences
Dry Eye Syndromes, Meige Syndrome, Blepharospasm, Hyperactivity
08/24
09/24
NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed
2
3
RoW
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma
11/21
12/21
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Recruiting
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
02/25
02/25
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Recruiting
2
60
RoW
HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2
Hutchmed
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
05/26
11/26
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
LUMMICAR STUDY 1, NCT03975907: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1/2
121
RoW
CAR-BCMA T Cells
CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University
Multiple Myeloma
12/24
12/25
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
46
RoW
YK012, YK012 for Injection
Excyte Biopharma Ltd
B-cell Acute Lymphoblastic Leukemia
12/26
06/27
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Recruiting
1/2
107
RoW
TQB3909 tablet
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/25
06/26
NCT05104775: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Recruiting
1
58
RoW
GNC-035
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Hematologic Malignancies
06/25
12/25
GLB-001-02, NCT06378437: A Study of GLB-001 in Patients With Myeloid Malignancies

Recruiting
1
108
RoW
GLB-001, GLB-C183-A-2
Hangzhou GluBio Pharmaceutical Co., Ltd.
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy
12/26
12/27
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting
1
98
RoW
HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study
Hutchmed
Hematological Malignancies
10/27
12/27
ICP-CL-01201, NCT05728658: The Study of ICP-248 in Patients With Mature B-cell Malignancies

Recruiting
1
105
RoW
ICP-248
Beijing InnoCare Pharma Tech Co., Ltd.
Hematological Malignancies
08/24
10/26
NCT05363800: Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Recruiting
1
198
RoW
HRS-3738
Jiangsu HengRui Medicine Co., Ltd.
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
10/24
12/24
ELEGANCE, NCT04965259: Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort

Recruiting
N/A
2000
RoW
National Cancer Centre, Singapore, Duke-NUS Graduate Medical School, Singapore Phenome Centre, Nanyang Technological University, MiRXES Pte Ltd, Perspectum Asia Pte Ltd, Asian Microbiome Library Pte Ltd
Liver Diseases
12/26
12/26
NCT06609434: The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer

Not yet recruiting
N/A
111
NA
Radiofrequency ablation
Peking University Cancer Hospital & Institute
Colo-rectal Cancer, Liver Metastasis
12/26
12/26
NCT04724148: Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension

Recruiting
N/A
4
RoW
Fentanyl
Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Lishui hospital of Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Zhejiang University
Liver Cirrhosis, Portal Hypertension, Pain
11/24
11/24
BIOFLOW-China, NCT05667285: BIOFLOW-china Post-marketing Study (BIOTRONIK)

Terminated
N/A
122
RoW
BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System
Biotronik (Beijing) Medical Device Ltd., Biotronik AG
In-Stent Stenosis (Restenosis) of Coronary Artery Stent, Native Coronary Artery Stenosis
09/24
09/24
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting
N/A
160
RoW
No intervention
Takeda
Multiple Myeloma
06/27
06/27
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Yu, Lei
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
10/24
10/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
06/28
10/28
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Recruiting
2/3
520
RoW
HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo
Sunshine Lake Pharma Co., Ltd.
Chronic HCV Infection
04/23
04/23
NCT06363825: A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
2
57
RoW
camrelizumab, apatinib
Fujian Medical University
Advanced Hepatocellular Carcinoma
04/26
05/27
NCT05919680: A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Recruiting
2
36
US
NST-6179 Part A, NST-6179 Part B, Matched Placebo
NorthSea Therapeutics B.V.
Intestinal Failure Associated Liver Disease
06/25
06/25
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

Not yet recruiting
1/2
162
RoW
TQA3038 injection/placebo, Nucleotide drugs Control group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
09/26
09/26
NCT04211805: Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

Recruiting
N/A
450
RoW
Tenofovir Alafenamide 25 MG for arm (A), HBIg 200 IU im for infants, HBV vaccine 10 ug im for infants, Tenofovir Disoproxil Fumarate 300mg for arm (B)
New Discovery LLC
Hepatitis B, Chronic, Pregnancy Related
09/21
09/21
Davidson, Evelyne
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Active, not recruiting
3
3433
Europe, Canada, US, RoW
Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.
COPD, COPD Exacerbation
01/26
01/26
Cheng, Zhifeng
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis

Recruiting
4
300
RoW
Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei
Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd.
Low Bone Mineral Density, Postmenopausal Osteoporosis
06/25
12/25
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Recruiting
3
424
RoW
Victoza®., Metformin Hydrochloride, TQZ2451
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
12/21
12/21
RECAM, NCT04807348: Chiglitazar Added to Metformin for Type 2 Diabetes

Completed
3
533
RoW
Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage
Chipscreen Biosciences, Ltd.
Type 2 Diabetes
02/23
02/23
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Recruiting
3
672
RoW
PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo
PegBio Co., Ltd.
Type 2 Diabetes Mellitus (T2DM)
11/23
04/25
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

Active, not recruiting
3
408
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
T2DM (Type 2 Diabetes Mellitus)
03/25
09/25
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
551
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
Type 2 Diabetes Mellitus
03/25
12/25
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Recruiting
3
888
Europe, US, RoW
Orforglipron, LY3502970, Dapagliflozin
Eli Lilly and Company
Type 2 Diabetes
10/25
10/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Completed
3
514
RoW
HLX14, Prolia®
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Postmenopausal
12/23
07/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Completed
3
168
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes
10/24
10/24
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
02/26
03/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed
2
233
Europe, Japan, US, RoW
LY3473329, Placebo
Eli Lilly and Company
Lipoprotein Disorder
03/24
03/24
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
NCT06118021: A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Recruiting
2
200
RoW
HS-20094, HS-20094 injection, Placebo, Placebo injection
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Overweight and Obesity
08/24
10/24
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Not yet recruiting
2
300
RoW
MDR-001, Placebo
MindRank AI Ltd
Obesity, Overweight and Obesity
07/25
09/25
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Recruiting
2
320
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
06/25
06/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

Not yet recruiting
N/A
1000
RoW
Continuous Glucose Monitoring System (GX-01S)
Nanjing First Hospital, Nanjing Medical University
Type1 Diabetes Mellitus
10/26
06/27
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Recruiting
N/A
2478
RoW
Denosumab, Teriparatide
Peking Union Medical College Hospital
Osteoporotic Fractures
09/26
09/26
Zhang, Zhuobo
CRAD-001-03, NCT05295173: A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Completed
3
1412
RoW
Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA
Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital
Acute Ischemic Stroke
06/23
06/23
NCT03789760: The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule

Completed
3
493
RoW
SaiLuoTong capsule, The effects of SaiLuoTong capsule on VaD, placebo
Shineway Pharmaceutical Co.,Ltd
Vascular Dementia
03/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting
2/3
132
RoW
B001, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Neuromyelitis Optica Spectrum Disorders
10/27
02/29
Ye, Qinyong
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05906719: Machine Vision Based MDS-UPDRS III Machine Rating

Recruiting
N/A
871
RoW
video recording
Ruijin Hospital, Second Affiliated Hospital of Soochow University, Beijing Hospital, Beijing Tiantan Hospital, Wuhan Union Hospital, China, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital
Parkinsonian Disorders, Machine Learning
04/24
04/24
COAST, NCT03653156: China Cognition and Aging Study

Recruiting
N/A
100000
RoW
Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Hunan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, Wuhan University Zhongnan Hospital, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Affiliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia
01/38
01/38
CFAN, NCT03657732: The Chinese Familial Alzheimer's Network

Recruiting
N/A
40000
RoW
Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Wuhan University Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Affiliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital
Alzheimer Disease, Familial Alzheimer Disease (FAD)
01/38
01/38
Zhu, Liying
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
2
250
RoW
GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table
Sunshine Lake Pharma Co., Ltd.
Chronic HBV Infection
06/22
09/23
NCT04211805: Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

Recruiting
N/A
450
RoW
Tenofovir Alafenamide 25 MG for arm (A), HBIg 200 IU im for infants, HBV vaccine 10 ug im for infants, Tenofovir Disoproxil Fumarate 300mg for arm (B)
New Discovery LLC
Hepatitis B, Chronic, Pregnancy Related
09/21
09/21
Usdan, Lisa S
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
APC-APN-201, NCT06400615: Study That Tests AD109 in Patients Taking GLP-1 Drugs

Active, not recruiting
2
40
US
AD109
Apnimed
OSA
12/24
12/24
Youga, Henry
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26

Download Options